Vertex Pharmaceuticals Q1 2026 earnings beat and planned $10 billion acquisition

Statements (13)

1. ▲ Bullish

   Vertex stock surged on a surprise expansion for its kidney disease drugs

   investors.comSep 22, 2026 17:39 UTCHigh importance
2. ▲ Bullish

   Vertex's kidney drug success causes a 22% surge for this rival biotech company

   barrons.comSep 22, 2026 16:46 UTCHigh importance
3. ▼ Bearish

   Vertex Pharmaceuticals stock sinks as market gains

   finance.yahoo.comSep 18, 2026 21:50 UTC
4. ▲ Bullish

   Vertex Pharmaceuticals shares rallied following Sionna's clinical trial failure

   finance.yahoo.comAug 12, 2026 03:41 UTC
5. ▲ Bullish

   Vertex Pharmaceuticals reported strong commercial momentum in its second quarter.

   finance.yahoo.comAug 12, 2026 01:41 UTC
6. ▲ Bullish

   Vertex Pharma stock surged Monday after its competitor Sionna Therapeutics missed the mark for its highly anticipated cystic fibrosis treatment.

   investors.comAug 10, 2026 13:22 UTCHigh importance
7. ▲ Bullish

   Vertex Pharmaceuticals Inc is likely to see its stock price rise following its Q2 2026 earnings report showing revenue surges of 12% year-over-year.

   finance.yahoo.comAug 4, 2026 05:08 UTC
8. ▲ Bullish

   Vertex Pharmaceuticals Inc reported total revenue of $3.3 billion in Q2 2026, up 12% year-over-year.

   finance.yahoo.comAug 4, 2026 05:08 UTCHigh importance
9. ▲ Bullish

   Vertex Pharmaceuticals Inc reported JOURNAVX revenue of $50 million in Q2 2026, up 150% year-over-year.

   finance.yahoo.comAug 4, 2026 05:08 UTCHigh importance
10. ● Neutral

    Vertex Pharmaceuticals reports Q2 2026 post-market on August 3

    247wallst.comAug 3, 2026 19:02 UTC
11. ▲ Bullish

    Vertex Pharmaceuticals reaffirms full-year guidance in the range of $12.95B to $13.10B

    247wallst.comAug 3, 2026 19:02 UTCHigh importance
12. ▲ Bullish

    Vertex Pharmaceuticals is likely to see a positive market reaction following its Q2 2026 earnings report with guidance reaffirmed.

    247wallst.comAug 3, 2026 19:02 UTC
13. ▲ Bullish

    Vertex Pharmaceuticals reported $2.99 billion in revenue for the second quarter, up 8.2% year on year.

    finance.yahoo.comAug 2, 2026 04:36 UTC